Debra Stephanie Barker
Technik-/Wissenschafts-/F&E-Leiter bei DESTINY PHARMA PLC
Vermögen: 36 120 $ am 30.04.2024
Profil
Dr. Debra Stephanie Barker, MD, is a Senior Independent Non-Executive Director at Arix Bioscience Plc and a Senior Independent Non-Executive Director at Destiny Pharma Plc.
She is on the Board of Directors at Arix Bioscience Plc, Arix Bioscience /Venture Capital/, CureVac NV, Destiny Pharma Plc, BerGenBio ASA, Hutman Diagnostics AG and CureVac SE.
Dr. Barker was previously employed as a Chief Medical & Development Officer by Polyphor AG and a Head-Development, Anti-Infectives & Immunology by Novartis AG.
She received her graduate degree from King's College London and a doctorate degree from Queens' College Cambridge.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DESTINY PHARMA PLC
0,09% | 25.05.2023 | 88 461 ( 0,09% ) | 19 661 $ | 30.04.2024 |
CUREVAC N.V.
0,00% | 15.03.2024 | 7 125 ( 0,00% ) | 16 459 $ | 30.04.2024 |
Aktive Positionen von Debra Stephanie Barker
| Unternehmen | Position | Beginn |
|---|---|---|
| BERGENBIO ASA | Direktor/Vorstandsmitglied | 13.03.2019 |
| DESTINY PHARMA PLC | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2023 |
| CUREVAC N.V. | Direktor/Vorstandsmitglied | 22.06.2022 |
| ARIX BIOSCIENCE PLC | Direktor/Vorstandsmitglied | 10.08.2022 |
Hutman Diagnostics AG
 Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Direktor/Vorstandsmitglied | - |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Direktor/Vorstandsmitglied | - |
Arix Bioscience /Venture Capital/
 Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Direktor/Vorstandsmitglied | 01.08.2022 |
Ehemalige bekannte Positionen von Debra Stephanie Barker
| Unternehmen | Position | Ende |
|---|---|---|
| SPEXIS AG | Technik-/Wissenschafts-/F&E-Leiter | 31.12.2018 |
| NOVARTIS AG | Corporate Officer/Principal | - |
Ausbildung von Debra Stephanie Barker
| King's College London | Graduate Degree |
| Queens' College Cambridge | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| NOVARTIS AG | Health Technology |
| SPEXIS AG | Health Technology |
| DESTINY PHARMA PLC | Health Technology |
| BERGENBIO ASA | Health Technology |
| ARIX BIOSCIENCE PLC | Finance |
| CUREVAC N.V. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Hutman Diagnostics AG
Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Health Technology |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Finance |
